Pfizer CRZ 250 (Xalkori 250 mg)

Generic Name: crizotinib

Pill imprint Pfizer CRZ 250 has been identified as Xalkori 250 mg.

Xalkori is used in the treatment of non-small cell lung cancer and belongs to the drug class multikinase inhibitors. There is positive evidence of human fetal risk during pregnancy. Xalkori 250 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for Pfizer CRZ 250

Xalkori
Generic Name:
crizotinib
Imprint:
Pfizer
CRZ 250
Strength:
250 mg
Color:
Pink
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Multikinase inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
N - Not a controlled drug
Manufacturer:
Pfizer Inc.

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web3)